Memantine: An oral NMDA antagonist for the treatment of moderate-to-severe Alzheimer's disease
Date of Original Version
Memantine (Namenda, Forest) is the newest medication to receive FDA approval for the treatment of Alzheimer's disease and the first to be approved with a moderate-to-severe indication. All previously approved Alzheimer's disease treatments belong to the cholinesterase inhibitor class and are approved with a mild-to-moderate indication. Memantine has been used for more than 10 years in Germany and features a novel mechanism of action: N-methyl-D-aspartate (NMDA) antagonism. It has been shown to be effective in double-blind, placebo-controlled trials as monotherapy and in combination therapy with the cholinesterase inhibitor donepezil in patients with moderate-to-severe Alzheimer's disease. Memantine has also shown positive treatment effects in patients with vascular dementia. It has a favorable adverse effect profile with no adverse effect occurring at more than twice the rate of placebo. The availability of memantine will give clinicians and caregivers a new safe and effective treatment option for Alzheimer's disease. Forest Laboratories has filed an sNDA seeking a mild-to-moderate Alzheimer's disease indication for memantine as monotherapy.
Feret, Brett, and Robert Dicks. "Memantine: An oral NMDA antagonist for the treatment of moderate-to-severe Alzheimer's disease." Formulary 39, 2 (2004): 91-103. https://digitalcommons.uri.edu/php_facpubs/1320